Evidence map›Paper›PMID 31118965›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2019

Preliminary Study to Evaluate Three Different Treatments on Stable Chronic Obstructive Pulmonary Disease Patients Based on Markov Model.

Xue-Qing Yu, Shu-Guang Yang, Han Li, Yang Xie, Jian-Sheng Li, Pan Zhang

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xue-Qing YuDepartment of Respiratory Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine, Ren-min Road 19, Zhengzhou, Henan 450000, China.ORCID 0000-0002-0281-322X
Shu-Guang YangHenan University of Chinese Medicine, Jin-shui East Road 156, Zhengzhou, Henan 450046, China.ORCID 0000-0002-6152-1040
Han LiDepartment of Respiratory Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine, Ren-min Road 19, Zhengzhou, Henan 450000, China.
Yang XieDepartment of Respiratory Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine, Ren-min Road 19, Zhengzhou, Henan 450000, China.ORCID 0000-0002-6444-6090
Jian-Sheng LiDepartment of Respiratory Diseases, the First Affiliated Hospital of Henan University of Chinese Medicine, Ren-min Road 19, Zhengzhou, Henan 450000, China.ORCID 0000-0002-2714-9353
Pan ZhangDepartment of Critical Care Medicine, The Third People's Hospital of Henan Province, Fu-niu Road 198, Zhengzhou, Henan 450006, China.
First Affiliated Hospital of Henan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluates the costs and utilities of different treatment strategies for stable chronic obstructive pulmonary disease (COPD) patients based on Markov model and provides guidance for clinical decision and health policy making. Patients with stable COPD from four subcenters had been investigated. A Markov model with three states, namely, GOLD 1-2, GOLD 3-4, and death, was built using TreeAge Pro 2011 software. Cost-utility ratio (CUR) and incremental cost-utility ratio (ICUR) from forty Markov circles were applied to measuring the economics evaluation of three different treatments. A total of 236 stable COPD patients were randomly assigned into three groups, Western medicine group (79 cases), traditional Chinese medicine (TCM) group (79 cases), and combined group (78 cases). The results of Markov cohort simulation showed that the accumulative quality-adjusted life years (QALYs) of the three above groups per 100 000 people in 40 years were 1 702 773, 1 616 797, and 1 709 668 years, respectively, and the accumulative costs were 13 582 138 466, 1 207 904 113, and 14 656 607 371 Yuan, respectively. The CURs of the three groups were 87 235, 74 602, and 87 223 Yuan/QALY, respectively. ICURs of combined group were 8 707 and 41 705 Yuan as against Western medicine group and TCM group, respectively. Therefore, combined treatment has a lower cost, higher health output, and more socioeconomic benefits in the long run. Markov model is recommended to conduct health economics evaluation of different treatments for COPD.

Identifiers

PMID31118965
PMCPMC6500607
OpenAlexW2938501405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.